Supratentorial cancer

Summary

Supratentorial cancer (MONDO:0002071) is a cancer and 3 clinical trials. Top therapeutic interventions include lonafarnib. A subtype of brain cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	supratentorial cancer
Mondo ID	MONDO:0002071
MeSH	D015173
DOID	DOID:1659
NCIT	C4964
UMLS	C0751589
MedGen	155589
GARD	0027597
Anatomy (UBERON)	UBERON:0001893
Is cancer (heuristic)	yes

Also known as: malignant supratentorial neoplasm · malignant supratentorial tumor · malignant supratentorial tumour · supratentorial neoplasms, malignant

Disease family

This is a subtype of brain cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › supratentorial cancer

Related subtypes (8): brain germinoma, brain sarcoma, cerebral ventricle cancer, infratentorial cancer, intracranial primitive neuroectodermal tumor, brain glioma, cancer of cerebellum, metastatic malignant neoplasm in the brain

Subtypes (4): childhood choroid plexus carcinoma, cerebral hemisphere cancer, diencephalic cancer, supratentorial primitive neuroectodermal tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00102648	PHASE1	ACTIVE_NOT_RECRUITING	Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
NCT02457845	PHASE1	COMPLETED	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
NCT06036732	Not specified	UNKNOWN	A New Approach in Intensive Care Unit Consciousness Assessment: FIVE Score

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LONAFARNIB	4	1
CHEMBL4228794	0	1